Jallal To Lead Immunocore, Building On Partnership She Forged At MedImmune

A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.

Young woman wearing in climbing equipment standing in front of a stone rock outdoor and preparing to climb, rear view

AstraZeneca PLC Vice President Bahija Jallal, the head of its MedImmune LLC subsidiary, is leaving her corporate home of more than 12 years to take on the role of CEO at Immunocore Ltd., a clinical-stage firm focused on bispecific antibody candidates for cancer and other diseases – which has been partnered with AstraZeneca since 2014.

The Jan. 4 announcement came the same day as another AstraZeneca exec, Executive VP Mark Mallon, departed to take the...

Welcome to Scrip

Create an account to read this article

More from Leadership

Executives On The Move: Instylla And Geron Get New CEOs

Recent moves in the industry include changes at the top at Meitheal Pharmaceuticals, Ardelyx and AIRNA, plus five companies get new CMOs.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By 

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By 

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

Executives On The Move: Changes At The Top At Novo Nordisk Plus Other New CEOs

Flashpoint Therapeutics and Nerviano Medical Sciences (Shanghai) have new leaders, while Genmab hires an ex-Gilead Sciences executive.

More from Scrip

Interest In PTC’s Sephience Launch Overshadows FDA’s Vatiquinone Rejection

 

PTC said it got a complete response letter for the Friedreich’s ataxia drug, with the agency asking for an additional clinical trial.

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Egetis Eyes Swift US Submission For Emcitate

 
• By 

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.